MX2021011335A - Antagonistas de ngf para uso medicinal. - Google Patents

Antagonistas de ngf para uso medicinal.

Info

Publication number
MX2021011335A
MX2021011335A MX2021011335A MX2021011335A MX2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A MX 2021011335 A MX2021011335 A MX 2021011335A
Authority
MX
Mexico
Prior art keywords
ngf
medical use
ngf antagonists
polypeptides
trka
Prior art date
Application number
MX2021011335A
Other languages
English (en)
Spanish (es)
Inventor
Shyr Jiann Li
Lam Nguyen
Hangjun Zhan
Fawn Qian
Richard Chin
Qingyi Chu
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of MX2021011335A publication Critical patent/MX2021011335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2021011335A 2019-03-20 2020-03-20 Antagonistas de ngf para uso medicinal. MX2021011335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821438P 2019-03-20 2019-03-20
PCT/US2020/023846 WO2020191289A1 (en) 2019-03-20 2020-03-20 Ngf antagonists for medical use

Publications (1)

Publication Number Publication Date
MX2021011335A true MX2021011335A (es) 2022-01-06

Family

ID=72521232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011335A MX2021011335A (es) 2019-03-20 2020-03-20 Antagonistas de ngf para uso medicinal.

Country Status (10)

Country Link
US (1) US20220169740A1 (https=)
EP (1) EP3941933A4 (https=)
JP (1) JP2022525754A (https=)
KR (1) KR20220066002A (https=)
CN (1) CN113840831A (https=)
AU (1) AU2020240120A1 (https=)
BR (1) BR112021018156A2 (https=)
CA (1) CA3133104A1 (https=)
MX (1) MX2021011335A (https=)
WO (1) WO2020191289A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
KR20230005875A (ko) * 2020-04-22 2023-01-10 킨드레드 바이오사이언시스, 인코포레이티드 수의학 용도를 위한 장시간-작용성 항-il31 항체
AU2022329459A1 (en) 2021-08-20 2024-02-29 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
EP4419547A1 (en) * 2021-10-21 2024-08-28 Petmedix Ltd. Proteins comprising the extracellular domain of p75ntr
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
KR20250141832A (ko) * 2023-02-09 2025-09-29 펫메딕스 리미티드 P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
GB0020504D0 (en) * 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2007059574A1 (en) * 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US7342146B2 (en) * 2006-01-11 2008-03-11 Industrial Technology Research Institute Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
JPWO2015064621A1 (ja) * 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
WO2016035052A1 (en) * 2014-09-05 2016-03-10 Nvip Pty Ltd Anti-nerve growth factor antibodies for treating itching
US9517238B2 (en) * 2014-11-07 2016-12-13 Children's Hospital Medical Center Compositions and methods for treating allergic inflammation through inhibition of NTRK1
US12297272B2 (en) * 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体

Also Published As

Publication number Publication date
WO2020191289A1 (en) 2020-09-24
BR112021018156A2 (pt) 2021-11-16
KR20220066002A (ko) 2022-05-23
US20220169740A1 (en) 2022-06-02
AU2020240120A1 (en) 2021-09-30
JP2022525754A (ja) 2022-05-19
CA3133104A1 (en) 2020-09-24
EP3941933A1 (en) 2022-01-26
EP3941933A4 (en) 2023-07-26
CN113840831A (zh) 2021-12-24

Similar Documents

Publication Publication Date Title
MX2021011335A (es) Antagonistas de ngf para uso medicinal.
MX2024012304A (es) Anticuerpos anti-il31 para uso veterinario
NZ757956A (en) Il4/il13 receptor molecule for veterinary use
MX2021004313A (es) Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
MX2022013192A (es) Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
MX2022010224A (es) Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
GEP20237528B (en) Antibodies against signal-regulatory protein alpha and methods of use
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
PH12017500994A1 (en) Anti-pd-1 antibodies and methods of use thereof
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
EA201190273A1 (ru) Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз
MX2022013149A (es) Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
MY189692A (en) Anti-ox40 antibodies and methods of use thereof
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EP3964527A3 (en) Combination therapy for cancer
CY1123007T1 (el) Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b
EA201790213A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
JOP20190093A1 (ar) أجسام مضادة لـ il-33 واستخداماتها
JOP20190175A1 (ar) مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR)
BR112012026718A2 (pt) antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma